Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCTL | Q9NXS2 | 6/20 | 0.60 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.47 |
| ▸ | QPCT | Q16769 | 4/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397189 | 0.87 | QPCTL (0.66) | QPCTLP2RX7 | |
| SCHEMBL2397851 | 0.83 | QPCTL (0.84) | QPCTLP2RX7QPCT | |
| SCHEMBL2396207 | 0.81 | QPCTL (0.66) | QPCTLP2RX7QPCT | |
| SCHEMBL2396002 | 0.80 | QPCTL (0.84) | QPCTLP2RX7 | |
| SCHEMBL2395959 | 0.79 | QPCTL (0.66) | QPCTLP2RX7QPCT | |
| SCHEMBL2396678 | 0.78 | QPCTL (0.66) | QPCTLP2RX7 | |
| SCHEMBL2399845 | 0.78 | QPCTL (0.63) | QPCTLP2RX7QPCT | |
| SCHEMBL2397479 | 0.77 | QPCTL (0.64) | QPCTLP2RX7 | |
| SCHEMBL2395188 | 0.77 | QPCTL (0.59) | QPCTLP2RX7QPCT | |
| SCHEMBL2398286 | 0.77 | QPCTL (0.62) | QPCTLP2RX7QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542549-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-05-11 | — | — | EP | claimed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | claimed |
| EP-2542549-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-05-11 | — | — | EP | disclosed |
| EP-2542549-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-05-11 | — | — | EP | disclosed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20110224259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011107530-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224259-A1 | NOVEL INHIBITORS | QPCT, GLUL, GLS | QPCTL 5/4885P2RX7 3232/4885QPCT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.